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Abstract
Ecdysteroids are widely used as inducers for gene-switch systems based on insect ecdysteroid receptors and genes of interest placed
under the control of ecdysteroid-response elements. We review here these systems, which are currently mainly used in vitro with
cultured cells in order to analyse the role of a wide array of genes, but which are expected to represent the basis for future gene
therapy strategies. Such developments raise several questions, which are addressed in detail.
First, the metabolic fate of ecdysteroids in mammals, including humans, is only poorly known, and the rapid catabolism of
ecdysteroids may impede their use as in vivo inducers.
A second set of questions arose in fact much earlier with the pioneering “heterophylic” studies of Burdette in the early sixties on the
pharmacological effects of ecdysteroids on mammals. These and subsequent studies showed a wide range of effects, most of them
being beneficial for the organism (e.g. hypoglycaemic, hypocholesterolaemic, anabolic). These effects are reviewed and critically
analysed, and some hypotheses are proposed to explain the putative mechanisms involved.
All of these pharmacological effects have led to the development of a wide array of ecdysteroid-containing preparations, which are
primarily used for their anabolic and/or “adaptogenic” properties on humans (or horses or dogs). In the same way, increasing numbers
of patents have been deposited concerning various beneficial effects of ecdysteroids in many medical or cosmetic domains, which
make ecdysteroids very attractive candidates for several practical uses.
It may be questioned whether all these pharmacological actions are compatible with the development of ecdysteroid-inducible gene
switches for gene therapy, and also if ecdysteroids should be classified among doping substances.
Abbreviation:
20E 20-hydroxyecdysone
2d20E 2-deoxy-20-hydroxyecdysone
2dE 2-deoxyecdysone
BAH bisacylhydrazine
BmEcR Bombyx mori EcR
CfEcR Choristoneura fumiferana EcR
CfUSP Choristoneura fumiferana USP
CHO Chinese hamster ovary
CMV cytomegalovirus
DBD DNA-binding domain
DmEcR Drosophila melanogaster EcR
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AbbE ecdysone
EcR ecdysteroid receptor
EcRE ecdysteroid response element
EHT effective half-time
ERE oestrogen response element
GR glucocorticoid receptor
GRE glucocorticoid response element
HEK human embryonic kidney
HvEcR Heliothis virescens EcR
LBD ligand binding domain
murA muristerone A
PKA protein kinase A
polB polypodine B
ponA ponasterone A
PPAR peroxisome proliferator-activated receptor
RAR retinoic acid receptor
RXR retinoid X receptor
TR thyroid receptor
USP ultraspiracle
VDR vitamin D receptor
VEGF vascular endothelial growth factor
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Introduction
Ecdysteroids (zooecdysteroids) are steroid hormones that
control moulting and reproduction of arthropods. Whether they fulfil
hormonal functions in other invertebrate groups is still a matter of
debate. In 1966, the discovery of the same molecules
(phytoecdysteroids) in several plant species made them easily
available in large amounts, and this allowed pharmacological studies
to be initiated on mammals. Such studies were at first undertaken
in the hope of developing safer and more specific insecticides, and
it was quickly shown that these molecules were not toxic to
mammals. On the other hand, they displayed a wide array of rather
beneficial pharmacological effects (e.g. against diabetes or asthenia),
thus providing a plausible explanation for the properties of several
plant species widely used in traditional medicine. Although they
have been detected in ca. 6% of plant species analysed so far (Dinan,
2001), phytoecdysteroids are not so frequent in plant species used
as human food (with the noticeable exception of spinach; Bathory
et al., 1982; Grebenok et al., 1991). More than 300 different
ecdysteroids have been isolated from animal and plant sources (all
their structures can be found in the Ecdybase, http://ecdybase.org).
Ecdysteroids are structurally quite different from
mammalian steroids, and they are not expected to bind to vertebrate
steroid receptors. Soon after the isolation and cloning of Drosophila
melanogaster ecdysteroid receptor proteins, it appeared very
attractive to use them for designing inducible gene systems in
mammalian cells. Such a system has been commercially developed
by Invitrogen® and the potential use of ecdysteroid receptors for
gene therapy is being investigated. The different ecdysteroid-based
gene-switch systems will be reviewed in the first part of this article.
The in vivo use of ecdysteroids as inducers taken orally
raises questions about their uptake, metabolism and half-life in
mammals including humans, a topic which has not been extensively
investigated up to now (Sláma and Lafont, 1995), and this question
will be addressed in the second part of this review.
The development of ecdysteroid-regulated gene switches
seems, however, to have neglected much of the previous
pharmacological studies which showed the interference of
ecdysteroids with many physiological processes in mammals and
humans. All these effects will be summarised in the third part, paying
special attention to the protocols used and the significance/
limitations of the results obtained. In the light of recent data, we
will present in the fourth section some working hypotheses, which
could explain how ecdysteroids might act on mammalian cells.
The reported effects (mainly the anabolic effects) led
initially to a (doping ?) use for high-performance sportsmen in the
Eastern Bloc Countries, but nowadays a large number of ecdysteroid-
based preparations are freely available on the market. Most of them
are proposed as legal and non-toxic muscle-promoting substances
for bodybuilders, but an extensive search on the web has led to
more surprising findings (e.g. recommended use for golfers or for
domestic animals). So, whether ecdysteroids should be considered
as doping substances and whether their use should be controlled
will be finally discussed.
Ecdysone-inducible gene expression systems
Basic requirements
Spatial and temporal control of heterologous gene
expression is an area of considerable and growing interest with
relevance to basic and applied biological and medical research,
including gene therapy and functional genomics. However, these
heterologous regulatory systems should interfere minimally with
the complex endogenous regulatory networks. Ideally, heterologous
modification of gene expression in host cells should give rapid,
robust, precise and reversible induction (or suppression) of the target
gene(s). The necessary criteria are thus (Saez et al., 1997; Bohl and
Heard, 1998; DeMayo and Tsai, 2001; Fussenegger, 2001; Graham,3 Lafont R., Dinan L. 2003.  Practical uses for ecdysteroids in mammals including humans: an update.  30pp.  Journal of Insect Science, 3:7, Available online:
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2002):
1. Specificity: the system should not interfere with endogenous
regulatory networks and should be activated exclusively by
exogenous nontoxic compounds.
2. Inducibility: the system should possess a low baseline
expression and a high induction ratio.
3. Bioavailability of the inducer: control should be effected
by a drug that readily penetrates tissue.
4. Reversibility: the elicitor should possess high
pharmacokinetic turnover to enable reversal and permit repeated
cycles of induction.
5. Low immunogenicity: the components of the system should
not elicit immune responses in the host.
6. Flexibility: it should be possible to modify the system to
take account of different tissue applications and to optimise the
system for each of these.
7. Dose-dependence: the extent of the response should be
dependent on the dose of elicitor applied.
Ecdysteroid receptors in arthropods
Ecdysteroid receptors are members of the nuclear receptor
superfamily (Laudet, 1997), which are characterised by a domain
structure. The N-terminal A/B-domain is highly variable and is
associated with transcriptional activation. The C-domain is highly
conserved and is involved in binding the receptor complex to specific
response elements in the DNA. The D-domain is variable and
represents a hinge region between the DNA-binding domain and
the ligand-binding domain (E-domain). The E-domain is not only
responsible for ligand binding, but also has been implicated in
receptor dimerisation and interactions with other transcriptional
activators. There may also be a C-terminal F-domain, which, if
present, is highly variable between even closely related nuclear
receptors (Kumar and Thompson, 1999). Nuclear receptors regulate
gene expression as dimers, either as homodimers or as heterodimers
with another member of the nuclear receptor superfamily. One of
the most promiscuous heterodimeric partners for vertebrate nuclear
receptors is RXR, of which the equivalent in insects is Ultraspiracle
(USP; Oro et al., 1990). In the case of ecdysteroid receptors, only
the EcR:USP (or EcR:RXR) (Yao et al., 1993) complex is able to
bind the ecdysteroid ligand with high affinity and the presence of
ecdysteroid promotes complex formation. The ecdysteroid binds to
the EcR protein. No definitive ligand for USP has been identified,
but it has been suggested that juvenile hormones (or methyl
farnesoate in Crustacea) may bind to this receptor component and
modify the transactivation capacity of the complex (Jones and Jones,
2000).
The most extensively studied ecdysteroid receptor system
in arthropods is that of Drosophila melanogaster, where three
isoforms (A, B1 and B2) of EcR occur (Koelle et al., 1991; Talbot
et al., 1993). These isoforms arise through alternative promoter
usage and differential splicing, resulting in different A/B-domains,
but they all possess common DNA- and ligand-binding domains.
The EcR isoforms show tissue- and stage-specificity. Although there
is only one form of USP in D. melanogaster, two or more isoforms
have been found in other arthropods. USP isoforms also show tissue-
and stage-specificity (Kapitskaya et al., 1996).
EcR and USP gene homologues have now been
characterised from a variety of arthropod species: Aedes aegypti
(Cho et al., 1995; Kapitskaya et al., 1996), Amblyomma americana
(Palmer et al., 1999), Bombyx mori (Swevers et al., 1996), Ceratitis
capitata (Verras et al., 1999), Chironomus tentans (Imhof et al.,
1993; Vögtli et al., 1999), Choristoneura fumiferana (Kothapalli et
al., 1995; Perera et al., 1999), Heliothis virescens (Martinez et al.,
1999c), Locusta migratoria (Saleh et al., 1998; Hayward et al.,
1999), Lucilia cuprina (Hannan and Hill, 1997; 2001), Manduca
sexta (Fujiwara et al., 1995; Jindra et al., 1997), Ostrinia nubilalis
(Albertsen et al., 2000), Sarcophaga crassipalpis (Rinehart et al.,
2001), Tenebrio molitor (Mouillet et al., 1997; Nicolai et al., 2000),
Uca pugilator (Durica et al., 2002).
The biochemical characterisation of ecdysteroid receptor
complexes lags well behind that of vertebrate steroid hormone
receptors and has been in a period of quiescence for the past decade,
as emphasis has been placed on the characterisation and expression
of the genes. The generally accepted ligand for ecdysteroid receptors
in arthropods is 20E, but this does not preclude the other ecdysteroids
being significant at particular stages of development or in certain
tissues (Wang et al., 2000). In fact, ecdysteroid receptor complexes
recognise a wide range of ecdysteroid structural analogues and
sophisticated structure-activity and molecular modelling studies are
now beginning to be performed (Dinan et al., 1999a; Wurtz et al.,
2000; Ravi et al., 2001; Kumar et al., 2002). Owing to the importance
of ecdysteroid receptors in the regulation of arthropod development,
they are seen as an appropriate target for the development of new
pest control agents. In the context of this review, the identification
of bisacylhydrazines as non-steroidal ecdysteroid agonists (Wing,
1988; Dhadialla et al., 1998) is particularly worth mentioning as, in
addition to several of these molecules being commercialised as
insecticides, other analogues appear appropriate as gene switching
elicitors. Antagonists for ecdysteroid receptors are also being
identified (Dinan et al., 1999b).
Ecdysteroid-responsive expression systems
Mammalian systems
Ecdysteroids are apparently not endogenously
generated components of mammalian systems. However,
Figure 1.  Structures of ligands used for ecdysteroid-inducible gene expression
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they are normal components of the diets of many animals.
The low mammalian toxicity of these compounds (Sláma
and Lafont, 1995), together with the specificity of the
ecdysteroid receptor complex (EcR and USP proteins),
indicate that a successful gene-switching system might be
developed from this system (Fig. 2). With regard to plant
systems (see below), there are a significant number (ca.
6% of higher terrestrial species) of plants which accumulate
phytoecdysteroids (Dinan, 2001). This may restrict the use
of steroidal and non-steroidal ecdysteroid analogues as
elicitors in plant systems.
Initial reports appeared in the early 1990s
(Christopherson et al., 1992; Thomas et al., 1993; Yao et
al., 1992; 1993). Christopherson et al. (1992) transfected a
human embryonic kidney cell line (HEK293) with DmEcR
and a reporter gene and assessed the ability of various
ecdysteroids and vertebrate steroids (all at 1 µM) to induce
reporter activity; E, 20E and polB and the vertebrate steroids
were inactive, while ponA and murA were active. The
domain structure of nuclear receptors allows the domains
to operate autonomously (however, this should not be taken
to mean that the domains operate exactly the same under
all circumstances). This permitted the ligand binding
domain of EcR to be fused with the DNA-binding and A/
B-regions of the GR (GGEc) and the demonstration of the
induction of a GRE-containing reporter gene by murA and
with the same ecdysteroid specificity as for EcR in the same
mammalian cells. MurA could also induce a reporter gene
via a chimeric receptor recognising a consensus oestrogen
response element (ERE). They also demonstrated that
replacement of a portion of the GR N-terminal activation
domain in GGEc with the activation domain of the Herpes
simplex viral protein (VP16) resulted in 5-fold greater
activity (Christopherson et al., 1992).
Yao et al. (1992) showed that USP could substitute
for RXR as a heterodimeric partner for RAR, TR, VDR
and PPAR and showed that, for many mammalian cells
types, cotransfection of USP with EcR was necessary to
make the cells ecdysteroid-responsive, demonstrating that
USP is an essential part of the ecdysteroid receptor complex.
Thomas et al. (1993) found that certain mammalian
cell lines (e.g. HeLa) could support ecdysteroid-responsive
transactivation while others (e.g. CV-1) could not. They
demonstrated that the factor responsible for this was RXR.
RXR could not be replaced by RAR-α, TR-α or COUP-
TF, but USP was an effective partner for EcR. MurA was
effective at enhancing the DNA-binding activity (as
assessed by gel-shift assays) of EcR:RXR, but not
EcR:USP. Interestingly, the ligand of RXR 9-cis-retinoic
acid, also enhanced the DNA-binding activity of EcR:RXR
complexes.
The system has been further developed (No et al.,
1996). The final form of this development (VgEcR) was
more specific and gave a lower basal activity than
tetracycline-responsive systems. The starting point for the
developments of No et al. (1996) was the observation that
mammalian cells cotransfected with EcR and USP only
produce a 3-fold induction on treatment with murA (1 µM).
To improve the induction ratio they carried out a number
of modifications. Replacement of USP by RXR gave 34-
fold induction. Creation of a fusion protein consisting of
an N-terminal truncation of EcR attached to the VP16
activation domain (generating VpEcR) gave 212-fold
induction. Inclusion of binding sites for the transcription
factor Sp1 into the reporter vector between minimal
promoter and the EcREs enhanced the induction by a further
5-fold.
Since the ecdysteroid response element might be
weakly activated by endogenous farnesoid X receptors
FXR, the EcRE (to give 2 different half-sites with a 1-
nucleotide spacer, AGGTCA-AGAACA, generating E/
GRE) and DBD of EcR (by mutating 3 amino acids in the
P-box of the DNA-binding domain, generating VgEcR)
have been modified to ensure that the response element
will only bind the modifed EcR. The transcription-
regulatory potential of EcR has been enhanced by replacing
the endogenous activation domain by the Herpes simplex
virus VP16 activation domain (DeMayo and Tsai, 2001).
The final system gives a 1200-fold induction with 1 µM
murA, without interference from glucocorticoid or
farnesoid.
No et al. (1996) also generated transgenic mice
harbouring an ecdysteroid-inducible promoter or a T-cell-
specific expression construct of VpEcR and RXR. Crossing
of these two strains of mice gave double transgenic
offspring, which were induced to generate the reporter gene
transcript specifically in the thymus by injection of murA
(10 mg/mouse). Mice expressing VpEcR and RXR were
healthy, fertile and apparently normal.
Yang et al. (1995) produced a Chinese hamster
ovary (CHO) cell line stably transfected with EcR isoform
B1 and showed that the cells produce functional receptor
of the correct Mr (105 kDa), which is recognised by specific
antibodies, binds to EcRE in gel-shift assays and mediates
reporter gene expression in a ligand-dependent manner
(ponA; 4 - 100 µM). The authors suggest that CHO cells
produce high levels of RXR, which can heterodimerise with Figure 2. General scheme for ecdysteroid-based gene switches.5 Lafont R., Dinan L. 2003.  Practical uses for ecdysteroids in mammals including humans: an update.  30pp.  Journal of Insect Science, 3:7, Available online:
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EcR to generate functional receptor complexes.
A parallel system using the Bombyx mori receptor
(Swevers et al., 1995; Swevers et al., 1996) has been
developed (Suhr et al., 1998), who found that BmEcR, in
conjunction with murA (1 µM) or RH5992 (tebufenozide;
1 µM) could effect high level transactivation of a reporter
gene in the absence of exogenous heterodimeric partner in
mammalian cells (HEK293 cells and African green monkey
CV-1 cells). BmEcR is much shorter (616 amino acids;
Swevers et al., 1995) and has less than 42% overall amino
acid identity with the B1 isoform of DmEcR (878 amino
acids; Suhr et al., 1998). It has been recognised that RXR
(which is present to at least some extent in most, if not all,
mammalian cells) is a reluctant heterodimerisation partner
for DmEcR (Thomas et al., 1993; Yao et al., 1993), but it
appears to be less reluctant for BmEcR. By creating
chimaeric EcRs consisting of Dm and Bm domains in
various combinations, Suhr et al. (1998) could demonstrate
that the regions responsible for high affinity, ligand-
dependent heterodimerisation in BmEcR were present in
the hinge region (D) and the ligand-binding (E) domain.
Only the D-region appears to be involved in
heterodimerisation of BmEcR with USP.
Hoppe et al. (2000) created a hybrid Drosophila/
Bombyx ecdysteroid receptor (DB-EcR), which is
independent of recombinant RXR, and demonstrated its
efficacy in vitro and in vivo.
The commercially available Invitrogen system
(http://www.invitrogen.com: Fig. 3) has been used to
regulate the expression of a wide range of transfected genes
in mammalian cells (Sawicki et al., 1998; Chen et al., 2000;
Lüers et al., 2000; Niikura et al., 2000; Rampazzo et al.,
2000; Abeysinghe et al., 2001; Baba et al., 2001; Cole et
al., 2001; Gill et al., 2001; Hennigan and Stambrook, 2001;
Iwata et al., 2001; Jana et al., 2001; Kondo et al., 2001;
Patrick et al., 2001; Schmidt and Fan, 2001; Shi et al., 2001;
Sparacio et al., 2001; Stauffer et al., 2001; Stolarov et al.,
2001; Wang et al., 2001; Xu et al., 2001; Yam et al., 2001;
Yarovoi and Pederson, 2001; Zhu et al., 2001; Chen et al.,
2002; Coulthard et al., 2002; Davis et al., 2002; Hashimoto
et al., 2002; Kuate et al., 2002; Kudo et al., 2002; Meents
et al., 2002; Mellon et al., 2002; Odero-Marah et al., 2002;
Plows et al., 2002; Vickers and Sharrocks, 2002; Wang et
al., 2002; Wolter et al., 2002; Xiao et al., 2003; Xu and
Mellgren, 2002; Zhang et al., 2002) and in a tissue-specific
manner in mice (No et al., 1996; Albanese et al., 2000;).
The literature on the application of ecdysteroid-regulated
transgenic systems is currently growing exponentially.
Wyborski et al. (2001) developed a bicistronic
expression vector from which VgEcR and RXR can be co-
expressed. They used the general cytomegalovirus (CMV)
promoter, but this can be replaced with a cell-type specific
promoter.
Albanese et al. (2000) developed a system for
mammary gland-specific expression of an ecdysteroid-
regulatable gene in mice and have examined the
pharmacokinetics of injected ponA in the animals. Serum
clearance was rapid (activity half-life = 48 min).
Karns et al. (2001) have developed an alternative
to the Invitrogen system. The basic system (Figure 4)
consists of the (i) plasmid pGAL4-EcR, encoding a fusion
protein of the yeast GAL4 DNA-binding domain and the
ligand-binding domain of the ecdysteroid receptor from
Choristoneura fumiferana, (ii) plasmid pVP16-mRXR,
encoding a fusion protein of the Herpes simplex
transcriptional transactivator VP16 and mouse RXR protein,
and which, in the presence of ecdysteroid-type ligands
heterodimerises with GAL4-EcR, (iii) an indicator and
selection plasmid, either pGAL4-EGFP-SV40-neo
(consisting of 5 copies of the GAL4 response element,
followed by the minimal promoter region of the major late
promoter from adenovirus, the coding region of enhanced
green fluorescent protein [EGFP], the SV40 promoter and
the neomycin resistance locus) or pGAL4-SEAP (for stable
transformation, containing 5 x the GAL4 response element
and the coding region of the SEAP protein as reporter gene)
iv) the BAH GS-E (1 - 15 µM). This system forms the basis
of RHeoGene’s RHeoswitch Technology. As RHeoGene
Figure 3. The Invitrogen system for mammalian cells; the elicitor is
muristerone A (murA) or ponasterone A (ponA). See text for further details
(www.invitrogen.com).
Figure 4. The RHeoGene system for mammalian cells; the elicitor depicted is
the bisacylhydrazine GS-E (1-[3-methoxy-2-ethylbenzoyl]-2-[3,5-
dimethylbenzoyl]-2-tert-butylhydrazine). See text for further details (Karns
et al., 2001).6 Lafont R., Dinan L. 2003.  Practical uses for ecdysteroids in mammals including humans: an update.  30pp.  Journal of Insect Science, 3:7, Available online:
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have access to a large number of BAH analogues
(RHeoChem Ligands) and EcR genes from a wide variety
of insect species (RHeocept Receptors), they are able to
identify BAH analogues which are specific for particular
EcR LBDs and, thus, have the possibility to regulate
multiple genes in a coordinated manner, and this is being
developed under the title of RHeoPlex Systems
(www.rheogene.com). Karns et al. (2001) also considered
the suitablitiy of GS-E as an in vivo inducer in mice and
obtained maximal induction of reporter protein in 6-12 hrs
and return to basal expression levels by 12-24 hrs.
Plant systems
Most of the published research in this area has been
conducted by the industrial research labs at Zeneca
Agrochemicals (now Syngenta) and has been based on the
ecdysteroid receptor protein from Heliothis virescens
(HvEcR), which was cloned and characterised (Martinez
et al., 1999c). This protein has most similarity to EcRs from
other lepidopteran species and is closely related to the B1
isoform from D. melanogaster (DmEcRB1). Transfection
of mammalian HEK293 cells (RXR-containing) with
HvEcR and a reporter gene resulted in induction of the
reporter gene by murA (50% response at ca. 5 µM), but
not by 20E (Martinez et al., 1999a). For the development
of the plant system (Fig. 5), a chimeric receptor consisting
of the hinge and ligand-binding domains of HvEcR was
fused to the transactivation domain of the Herpes simplex
VP16 protein and the DNA-binding domain of the
glucocorticoid receptor and transfected into tobacco
protoplasts. The use of the GR DNA binding domain
circumvents the need to incorporate USP/RXR into the
system, since glucocorticoid receptors bind to their response
elements as homodimers. The second component of the
gene regulatory system consisted of 6 copies of the
glucocorticoid response element fused to the minimal 35S
cauliflower mosaic virus (35SCaMV) promoter (conferring
expression in all tissues and throughout development) and
a β-glucuronidase gene. Although induction was observed
with murA (100 µM), its steroidal nature precludes its use
under field conditions. Consequently, the non-steroidal
BAH RH5992 (1 - 10 µM) was used as an elicitor. In
addition to being ecdysteroid agonists, these compounds
are not phytotoxic. Incorporating the regulatory and reporter
components via Agrobacterium tumefaciens transformation
generated transgenic lines of tobacco plants. Germination
of the transformed seeds in the presence of murA or
RH5992 resulted in induction of the reporter gene activity
(up to 420-fold). RH5992 is 100-fold more potent than
murA in this system, giving maximal activation at 12.5 µM
and 50% activation at ca. 1 µM (Martinez et al., 1999a).
Parallel studies using maize protoplasts compared chimeric
receptors involving ligand and hinge regions of either the
D. melanogaster or H. virescens EcR fused to the A/B/C-
domains of the glucocorticoid receptor, showed that
RH5992 activates in the presence of GRH, but not GRD
(Martinez et al., 1999b). On the other hand, murA (100
µM) activates in the presence of GRD, but not GRH. The
preferential activation of GRH by RH5992 is in accord with
the higher affinity of this BAH for lepidopteran EcR/USP
complexes than for dipteran complexes (Dhadialla et al.,
1998), but the lack of activation of GRH by murA is not
readily explained and seems to indicate that the
conformation of the LBD of the chimeric receptor is
significantly altered.
Unger et al. (2002) have developed a BAH-
regulated system for the control of male fertility in maize.
Ms45 is a nuclear male fertility gene, which is expressed
in anthers. Homozygous recessive mutants are male sterile.
The aim was to create a Ms45 construct which would allow
male fertility to be restored after application of an elicitor.
The hinge and ligand-binding domains (domains D-F) of
the Ostrinia nubilalis EcR gene were linked to the VP16-
GAL4 or C1-GAL4 transcription activators, under the
regulation of the Ubiquitin 1 promoter, which gave
constitutive expression of the receptor construct. The Ms45
promoter region was replaced by 5 copies of the yeast 17
bp UASG. Regulatory proteins containing the GAL4 DNA-
binding domain bind to UASG. The authors demonstrate
that treatment of transformed maize callus with
methoxyfenozide (10 µM) induces Ms45 expression.
Further, when incorporated into plants, the plants were male
sterile in the absence of methoxyfenozide, but fertility was
restored by treating plants with methoxyfenozide.
Padidam et al. (2002) have recently developed an
ecdysteroid receptor-based gene expression system based
on a modified Choristoneura fumiferana EcR and the BAH
methoxyfenozide and demonstrated its effectiveness in
transgenic Arabidopsis thaliana and Nicotiana tabacum.
In addition to ecdysteroid/BAH controllable
systems, other chemically inducible gene expression
systems for plants are also being investigated (reviewed in
Gatz and Lenk, 1998; Jepson et al., 1998). These systems
have been recently compared and reviewed (Padidam,
2003).
Figure 5. The Syngenta system for plant cells. See text for further details
(Martinez et al., 1999a&b).7 Lafont R., Dinan L. 2003.  Practical uses for ecdysteroids in mammals including humans: an update.  30pp.  Journal of Insect Science, 3:7, Available online:
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Fungi
When transfected into Saccharomyces cerevisiae,
DmEcR is able to transactivate a reporter gene in the
absence of USP/RXR or ecdysteroid (ponA or murA) (Dela
Cruz and Mak, 1997). Activation is EcRE-dependent, but,
unexpectedly, ecdysteroid- and heterodimerisation partner-
independent. Interestingly, high affinity specific binding
of [3H]ponA (Kd = 1.8 nM) by yeast extracts was dependent
on coexpression of EcR and USP (or RXR). Radiolabelled
hormone displacement assays for yeast-expressed EcR/USP
with ponA, murA, 20E and RH5849 (Dela Cruz and Mak,
1997) indicate similar specificity and affinity to D.
melanogaster ecdysteroid receptor complexes in insect
systems (Bidmon and Sliter, 1990). Thus, the situation
prevailing when ecdysteroid receptors are expressed in yeast
cells is apparently very different to that for mammalian or
plant cells.
Using the ecdysteroid receptor genes from
Choristoneura fumiferana (CfEcR and CfUSP) coexpressed
in yeast with a reporter gene containing EcREs, Tran et al.
(2001) showed that EcR and USP together (but not
individually) induced reporter gene expression in the
absence of ligand, with RH5992 (10 µM) only providing a
small enhancement in reporter gene expression. Deletion
of the A/B-regions of CfEcR, in conjunction with CfUSP,
still gave ligand-independent transactivation with some
enhancement on addition of RH5992. However, deletion
of the A/B-regions of CfUSP (generating Cf∆USP)
abolished reporter gene expression, regardless of whether
co-expression was with CfEcR or Cf∆EcR and in the
presence or absence of RH5992. Together, these data
showed that EcR:USP is not suitable for a ligand-dependent
transactivation assay in yeast. Replacement of USP with
RXRα, RXRβ or RXRγ, when co-expressed with EcR,
resulted in no induction of the reporter gene in the presence
or absence of RH5992. However, co-expression of GRIP1
(a member of the p160 family of coactivators) and
Cf∆EcR:RXR or Cf∆EcR:Cf∆USP resulted in significant
ligand-dependent transactivation of the reporter gene
activity. The system with RXRβ appeared to have a low
sensitivity to RH5992 and other BAHs and was not pursued
further. Comparison of three yeast systems
(∆EcR:∆USP:GRIP1,  ∆EcR:RXRα:GRIP1 and
∆EcR:RXRγ:GRIP1) with an insect cell CfEcR:USP-
containing system (L57; DmEcR-negative Kc cells
transfected with CfEcR and β-galactosidase reporter
controlled by 6 x EcRE and a minimal promoter) using a
range of BAHs and murA and ponA showed induction in
all systems by active compounds, but i) the degree of
induction was far lower in the yeast systems and ii) the
ecdysteroids were very much poorer inducers in  the yeast
∆EcR:∆USP system than in the insect cells and did not
induce the ∆EcR:RXR(α or γ) systems. Further, 9-cis-retinoic
acid (a natural ligand of RXR receptors) induced the
∆EcR:RXRα:GRIP1 and ∆EcR:RXRγ:GRIP1 systems,
complicating interpretation of results from these systems
if they were used in screening processes. In part these
problems may derive from poor access of test compounds
through the thick yeast cell wall or rapid export from the
cells. Tran et al. (2001) provide evidence that use of yeast
strains with mutations in certain ABC transporter pathway
loci results in improved sensitivity (100-fold for RH5992).
Tran et al. (2001) propose their transactivation assay as a
screen to identify potential insecticides with ecdysteroid
agonist activity.
 Commercially available systems
The system devised by No et al. (1996) has been
developed and commercialised by Invitrogen (http://
order.invitrogen.com/). The company provides kits
consisting of mammalian cells (CV-1, HEK293 and CHO)
stably expressing a functional ecdysteroid receptor from
pVgRXR, the inducing agent (now ponA) and a vector by
which the gene of choice can be introduced into the cells,
after introduction of the gene into the vector by simple
recombination using Cre recombinase. The components are
also available individually. The pVgRXR expression vector
includes VgEcR, RXR and a gene for Zeocin resistance,
which allows for selection of stable cells expressing the
heterodimeric receptor (VgEcR:RXR).
Stable ecdysteroid-inducible mammalian cell lines
can be difficult to establish because of either high basal
expression of the target gene or poor induction of gene
expression, because of low expression of the receptors
(VgEcR and RXR) or the transgene. Ideally, stable cell lines
expressing the receptors should be established first and the
cells should be screened by transient expression of an
ecdysteroid-regulatable transgene to identify those
expressing the receptor proteins effectively. An
improvement on Invitrogen’s pIND/lacZ reporter system
(which generates β-galactosidase activity has been reported
(Wakita et al., 2001), which uses a firefly luciferase reporter
system. This considerably reduces analysis time (15 s, rather
than 2 h) and obviates background interference from
endogenous β-galactosidase activity. A similar advance has
been suggested by Lüers et al. (2000) who prepared an
expression plasmid for green fluorescent protein (EGFP)
and the reporter protein of interest. The co-inducible
production of EGFP permits the visual verification of target
gene expression and the selection of expressing cells by
flow-cytometry.
As described above (Section 2.3.1), RHeoGene
LLC are commercialising their ecdysteroid receptor-based
gene switching system (www.rheogene.com) and are
identifying specific receptors/ligand pairs which allow the
simultaneous, but independent, regulation of transfected
genes (Kumar et al., 2002). Further, hybrid receptors are
being optimised to give very low basal activity and high
induction on addition of ligand (Palli et al., 2003). A two-
hybrid format switch where the GAL4 DNA-binding
domain was fused to CfEcR domains D, E and F and the
VP16 activation domain was fused to mouse RXR domains
E and F, transactivating a reporter gene under the control
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promoter was found to give the best combination with rapid
turn-on and turn-off responses on the addition and removal
of RG-102240 (GS-E), respectively.
Ecdysteroid systems vs. other systems
Fussenegger (2001) provides a comprehensive description
of the heterologous molecular switching systems currently under
consideration. Each has its own advantages, but none fulfils all the
desirable criteria perfectly. From the time of early studies, transgenic
ecdysteroid-inducible gene expression systems in mammalian cells
have appeared to possess lower basal activity and higher inducibility
than tetracycline-based systems (No et al., 1996). Senner et al.
(2001) compared 3 inducer systems  (tetracycline, dimerizer and
ecdysteroid) in one system (rat C6 glioma cells) under identical
conditions. Each system required transient transfection with two
plasmids (a regulator plasmid and a reporter plasmid) and treatment
with an elicitor (inducers for the ecdysteroid and dimerizer systems
and a repressor for the tetracycline system). The ecdysteroid system
provided the highest induced activity, but the authors conclude that
each of the systems may be beneficial, depending on what the
experimental goals are. Van Craenenbroeck et al. (2001) compared
the tetracycline and ecdysteroid systems to regulate the expression
of neurotransmitter receptors in mouse fibrosarcoma L929sA and
HEK293 cells. The tetracycline system resulted in higher levels of
the neurotransmitter receptors being expressed, but the ecdysteroid
system gave more tightly regulated expression. Moreover, this study
underlined the importance of the genetic background of the cells
being used.
Morgan et al. (1999) compare several exogenously
regulatable promoter systems for their suitability for the study of
the functions of genes implicated in aging.
Ecdysteroid specificity
Gene expression systems in mammalian and plants cells
possess markedly different ecdysteroid specificities to ecdysteroid
receptors in insect systems. Both the affinity and specificity seem
to be affected. Thus, the generally accepted endogenous hormone
in insects, 20E, is inactive in transgenic systems. Two
phytoecdysteroids, murA and ponA, are normally used to activate
the transgenic systems, but even these are required at least 100-fold
higher concentrations than in insect systems; e.g. EC50 values for
murA and ponA in the Drosophila melanogaster BII bioassay are
2.2 x 10-8M and 3.1 x 10-10M, respectively (Dinan et al., 1999a),
while concentrations of 1 - 10 µM are required to induce transgenic
expression. The basis of this altered affinity/specificity is not clear
and it could derive from: (i) altered metabolism, (ii) use of RXR,
rather than USP, (iii) altered transportation into cells, (iv) fusion of
the EcR ligand-binding domain to the GR DNA-binding domain
and/or VP16 to form VgEcR, (v) the different properties of
mammalian transcription factors, enhancers, repressors etc.
A limited investigation of the ecdysteroid specificity of
VgEcR/RXR in CV-1 cells has been performed (Saez et al., 2000).
MurA, ponA and 14-deoxymuristerone A were almost equivalently
active (EC50 = ca. 5 x 10-7M), with ponasterone C being moderately
active (EC50 = 2 x 10-5M), polB being weakly active and 20E,
inokosterone, makisterone A, E, 2-deoxyecdysone, 20E 22-acetate
and 2-deoxy-20-hydroxyecdysone being inactive or only very
weakly active at 10-4M. This study also showed that the presence of
a natural (9-cis-retinoic acid) or synthetic (LG268 or LG1069) RXR
ligands, while inactive in itself, potentiated the activity of ponA by
3- to 5-fold.
Availability of ligands
Ecdysteroids
MurA has only been isolated once in large amounts
(Canonica et al., 1972), and then from a Himalayan plant
(Ipomoea calonyction). Consequently, world supplies of
this phytoecdysteroid became very restricted and did not
suffice for full-scale trials of ecdysteroid-induced transgenic
systems. However, Sequoia Sciences (http://
www.sequoiasciences.com) report on their website that they
have recently re-isolated murA. PonA, which has been
isolated from several named plant species and which can
be chemically generated from 20E (Heinrich, 1970), is also
active. Examination of the ecdysteroid specificity in more
detail could result in the identification of more active
inducers. While in vitro work may not suffer unduely from
the poor activity of currently used ecdysteroid inducers,
other than having to use much larger amounts of expensive
chemicals, the in vivo prospects for transgenic systems using
ecdysteroids would be enormously enhanced if they were
as active as in insect systems.
Bisacylhydrazines (BAHs)
Bisacylhydrazines were identified as non-steroidal
agonists of ecdysteroid receptors in 1988 (Wing, 1988).
Their chemical simplicity, low mammalian toxicity and
selectivity for certain Orders of insects has led to several
being developed as insecticides (Dhadialla et al., 1998).
They could also be used for the induction of transgenic
systems (Carlson et al., 2001) and, as is apparent above,
RH-5992 has found application in this context. Further
analogues (e.g. GS-E; Fig. 1) have been identified which
appear to be more potent for use with mammalian systems
(Carlson, 2000). However, the very limited water solubility
of these compounds may limit their application in vivo.
Modified receptors
A further approach to overcoming the current lack
of really potent ligands for transgenic induction would be
to modify the ligand-binding domain of the transgenic EcR
to either enhance the affinity for a particular analogue, or
to alter the specificity, so that a readily available analogue
(e.g. 20E) or a non-dietary ecdysteroid is recognised.
Cloning and sequence data for ecdysteroid receptor proteins
(EcR and USP) from a range of arthropod species provide
the basis for site-directed mutagenesis to modify specific
amino-acid residues. Both this and the previous approach
require a more thorough understanding of ecdysteroid
receptor recognition, not only in D. melanogaster (Dinan
et al., 1999a; Ravi et al., 2001), but also in other arthropod
species and in transgenic systems. The ultimate goal of such
studies is to engineer a range of EcR proteins, some of which
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while others respond to selected ecdysteroids, but not to
other classes of agonists (Graham, 2002). Strategies are
being developed for the synthesis of further non-steroidal
ligands for selective activation of ecdysteroid receptors
(Tice et al., 2003) and for the targeted modification of ligand
specificity of ecdysteroid receptors (Kumar et al., 2002).
Registration problems
Development of ecdysteroid systems for human therapeutic
use may be hampered by the steroidal nature of ecdysteroids and
the insecticidal origin of BAHs, which may prejudice their use as
elicitors, this being in spite of the fact that both ecdysteroids and
BAHs have low mammalian toxicities and ecdysteroids are a normal
(but small) component of the human diet. For plant systems,
ecdysteroids per se cannot be considered because of penetration
problems and BAHs may not be acceptable because of the enhanced
risk of development of resistance to insecticidal analogues. However,
use might be restricted to specified crops under conditions where
exposure to sensitive insect species is minimal.
Biochemical problems
Although the systems developed to date are effective for
use in in vitro expression systems, the requirements for an effective
in vivo system are much more stringent. In this context, one can
identify the following aspects of ecdysteroid-regulatable systems
which would need to be improved in order to generate a medically
viable system:
• Integration of heterologous DNA into host cells is not site-
specific and is unpredictable with regard to copy number.
• The current systems are genetically complex, requiring both
VgEcR and RXR.
• The artificial transactivator is potentially immunogenic.
• RXR is a reluctant dimerization partner for EcR and, therefore,
very high cellular RXR concentrations are required.
Overexpression of RXR may results in pleiotropic effects in
mammals.
• The maximal expression levels achieved are modest.
• Most ecdysteroids are not very active. Only muristerone A
and ponasterone A are effective.
• Ecdysteroids are not orally available
• Ecdysteroids or ecdysteroid analogues are not likely to get
approval for human therapeutic use.
Prospects
There is little doubt that ecdysteroid-regulated transgenic systems
have considerable potential for in vitro work. The applied potential
is somewhat more questionable at present, owing to the following
current limitations: i) genetic complexity, ii) altered affinity and
selectivity of VgEcR for ligands and iii) potential problems in the
registration of ecdysteroids and BAHs for human therapeutic uses
or with plant transgenic systems. However, significant progress is
being made in designing chimaeric receptors which would allow
only one trans-acting factor to be transfected. It is only a matter of
time until the reasons for the altered affinity and selectivity of
ecdysteroid receptors in mammalian and plant cells are elucidated
and more efficient systems are developed either by identifying more
effective ligands or site-directed mutagenesis of EcR to enhance
affinity for currently used ligands. Although ecdysteroids and BAHs
are nontoxic to humans, general public resistance to steroids and
insecticides may hamper their registration.
Ecdysteroid metabolism in mammals, including humans
Although the question of mammalian metabolism is
certainly of importance for the practicability of the in vivo use of
ecdysteroid-inducible gene expression systems (with the aim of
using them for gene therapy), it is not well documented at the present
time. Ecdysteroids have a very low toxicity in mammals: in the
mouse, the LD50 of 20E is 6.4 g/kg (for intra-peritoneal injection)
and it is >9 g/kg when given orally (Matsuda et al., 1970; Ogawa et
al., 1974). Up to now, studies have concerned mice, rats, lambs and
humans, and all have shown that these molecules are short-lived in
mammals. Several strategies have been used to analyse the metabolic
fate of ecdysteroids.
Ecdysteroids are rapidly eliminated
In the case of humans, two different studies have been
performed. Simon and Koolman (1989) analysed the
pharmacokinetics of E and 20E (given orally, 0.2 mg/kg b.w.) to a
male volunteer, by monitoring with a radioimmunoassay the
subsequent plasma and urine titres. This gave an effective half-time
(EHT) of elimination of 4 hours for E and 9 hours for 20E. In lambs,
EHT for 20E was shown to depend strongly on the mode of
administration, with values of 0.4, 0.2 and 2 hours after oral,
intravenous and intramuscular administration, respectively (Simon
and Koolman, 1989). The method used did not allow the detection
of metabolites, if present. The half-life seems shorter in smaller
mammals, with reported values of 8.15 min for 20E in mice
(Dzukharova et al., 1987). More recently, Albanese et al. (2000)
found a plasma half-life of 48 min for ponA in mice after intra-
peritoneal injection of 750 µg of this compound.
Both urinary and faecal routes seem to be used for the
elimination of the administered molecules. In mice, the faecal route
was found to be the major one by Hikino et al. (1972a&b) and Lafont
et al. (1988), although Dzukharova et al. (1987) found that faecal
and urinary routes were equally important. Such a question can be
easily assessed only by the use of radiolabelled molecules, but no
data are available for humans. Kinetic studies in mice showed that
ecdysteroids were taken up by the liver and then excreted into the
gut via the bile (Hikino et al.,1972a&b; Lafont et al., 1988).
Metabolic conversions
Another question concerns whether ecdysteroids undergo
metabolic conversions in mammals. The presently available data
are not fully consistent. In mice, Girault et al. (1988) analysed the
faecal metabolites of injected E and isolated unchanged E, a major
metabolite identified by MS and proton NMR as 14-deoxyecdysone
together with molecules with a fully reduced B-ring and,
additionally, epimerized in position 3 (Figure 6A). Such a
metabolism is reminiscent of the hepatic reduction of the 4-en-3-
one on ring-A of vertebrate steroid hormones, whereas
dehydroxylation resembles that of bile acids and could result from
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More recent studies were performed on ingested 20E in
rats (Ramazanov et al., 1996) and humans (Tsitsimpikou et al.,
2001). In these cases only urine was analyzed. Ramazanov et al.
administered 20E to 40 rats (50 mg/kg) directly in stomach with a
special probe, and they collected urine (3.5 L) over the following
10 days. After several chromatographic steps, they isolated
unchanged 20E and three new metabolites, which were analyzed
by IR and mass spectrometry. The IR spectra showed the
disappearance of the signal at 650 cm –1 (7-en-6-one) and the
structures were deduced from MS data (Figure 6B).
Tsitsimpikou et al. (2001) analysed the urine of a volunteer
having ingested 20 mg of “Ecdysten™” (a commercial preparation
containing 20E – see section 6); they collected urine over 5 days
and analysed ecdysteroids by GC-MS after derivatization. They
found, together with 20E, two less hydroxylated metabolites, which
they tentatively identified as 2d20E and 2dE by comparison with
available reference molecules.
Mass spectrometry does not provide sufficient information,
and only NMR can allow an unambiguous determination of
structures. Anyway, it seems reasonable to assume that modification
of the B-ring and dehydroxylation are general features of ecdysteroid
metabolism in mammals.
Conclusions/prospects
There is rapid catabolism/elimination of ecdysteroids,
which means that large amounts would have to be used in order to
maintain circulating levels above the concentration required for gene
switches systems to be activated. Alternatively, slow-delivery
systems like subcutaneous implants represent another way to
maintain sustained ecdysteroid levels for several days (Albanese et
al., 2000). Another remaining question concerns the metabolism in
peripheral tissues. As we have seen with mice, the observed
conversions are most probably performed by hepatocytes and
intestinal bacteria. It would be of interest to determine whether other
mammalian tissues are able to metabolise ecdysteroids, and the
nature of the reactions they can perform.
Whether side-chain cleavage between C-20 and C-22 (and
possibly also between C-17 and C-20) can take place is a very
important question which remains to be investigated by using
ecdysteroids labelled on the steroid nucleus, as labelling on the side-
chain would be lost if such a reaction would occur. This question
seems particularly important for several reasons: (1) cleavage
between C-20 and C-22 would result in the formation of 21C steroids
that would share some resemblance with vertebrate neurosteroids
(Lafont and Sláma, 1995), and (2) in some pharmacological studies
rubrosterone (2β,3β,14α-trihydroxy-5β-androst-7-ene-6,17-dione)
was as active as 20E (Otaka et al., 1968).
Pharmacological effects of ecdysteroids on vertebrates
The pharmacological actions of ecdysteroids on vertebrates
have been reviewed in several previous articles (Burdette, 1962,
1972; Ogawa et al., 1974; Syrov, 1984, 1994; Sláma and Lafont,
1995; Xu et al., 1997; Syrov, 2000; Kholodova, 2001; Báthori,
2002). We will therefore focus on some aspects only, especially on
those where recent developments have occurred. The most important
data are summarised in Table 1.
Ecdysteroids and growth (Table 2)
The anabolic effects of several phytoecdysteroids (20E,
cyasterone, turkesterone, viticosterone E – see structures on
Ecdybase) on mice or rats were reported long ago (see e.g. Okui et
al., 1968; Syrov and Kurmukov, 1975a&b; 1976a-c, Syrov et al.,
1978, 1981a; Stopka et al., 1999). Growth-promoting effects have
also been more recently reported for pigs (Kratky et al., 1997) and
Japanese quails (Koudela et al., 1995; Sláma et al., 1996). In many
instances however, these effects are not spectacular when
considering the growth (weight) curves as they are observed during
certain phases of growth or for one sex only and, in many cases,
adequate statistical analyses are lacking. Nevertheless, even small
effects (i.e. <5 % increase) on growth could be of economical interest
for nutritionists, but their firm establishment requires the use of
large numbers of animals, which is hardly feasible with large
mammals. The addition of E to sheep food increases body growth
rate and also wool growth (Purser and Baker, 1994). Surprisingly,
these effects were obtained with minute amounts of ecdysone (0.02
µg/kg per day!), and were more evident when animals were fed on
a poor quality diet, which indicates that E improves food utilization.
In this case, it has been suggested that the effect results from the
toxicity of E towards rumen protozoa, but this has not been fully
Figure 6. Major E and 20E metabolites in Mammals (see text for details).  A:
E metabolites (2-4) isolated from murine faeces (Girault et al., 1988);  B: 20E
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Table 1.  Pharmacological effects of ecdysteroids on mammals or humans (see also Sláma and Lafont, 1995 for additional references – in red : references to
patents)
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Biologicalarea EcdysteroidEffects References
Slightstimulationofgrowthinmice(bydietary20Eor
cyasterone)
Hikino etal. ,1969
NoeffectofdietaryponA , 20Eandinokosteroneonrat
growth
Matsuda etal. ,1970
Stimulationofgrowthinrats(bydietaryviticosterone
E, 20E, turkesteroneandturkesteronetetraacetate)
SyrovandKurmukov,1975a,1976a,b
Stimulationofg rowthinsheepbyE  PurserandBaker,1994
Simulationofg rowthin quailsbydietary20E Koudela etal. ,1995;Sláma etal. ,1996
Stimulationofg rowthin pigs Krátky etal. ,1997
Stimulationofg rowthinmice(b y20Einjections) Stopka etal. ,1999
Dietary20E(5mg/kg)a cceleratesbonefracture
healingp rocessinrats
Syrov etal. ,1986a
20Epossesseswoundhealingandskinregenerating
properties
LinandLin,1989;MeybeckandBonté,1990,1993;
Meybeck etal. ,1994
20E(100 Pg/ml)promoteskeratinocytedifferentiation
invitro
Detmar etal. ,1994
Einducesbreastandlungneoplasticlesionsinmice  El-Mofty etal. ,1994
20Easskinmetabolism-activatingandanti-wrinkling
agent
Tsujietal.1995a
PonAinahairtonic preparation  Tsuji etal. ,1995b
Dietaryecdysteroids(20E , cyasterone, turkesterone,
5mg/kg)acceleratewoundhealinginrats
SyrovandKhushbaktova,1996
20Eandsome analoguesinhibit psoriasis  Inaoka etal. ,1997
20E(200 Pg/ml)stimulatesproliferationofhuman
umbilicalveinendothelialcells
Lin etal. ,1997
Dietaryecdysteroids(20E , turkesterone,...)enhance
erythro-poiesisinrats
Syrov etal. ,1997b
Phytoecdysteroidsuseforthetreatmentofburnsand
wounds
Darmograi etal. ,1998
20E promotes proliferationofosteoblast-likecells Gao etal. ,2000
20Eand polypodineBshowembr yotoxicity Kosar etal. ,1997
Ecdysteroidsmightincreasemilkproductionin
mammals
KhalitovaandSyrov,1998
Dietary20E(5-10mg/kg)enhancessexualfunctionin
rats
Mirzaev etal. ,1992,2000
Injectedecdysteroids(20E , 5mg/kg)stimulateprotein
synthesisinmouseliver;thiseffectcorrespondstoa
stimulationoftranslation
Okui etal. ,1968;Otaka etal. ,1968,1969a,b;
20Estimulates proteinsynthesisinmouseor gans Todorov etal. ,2000
Hypoglycaemic formulationcontaining20E  UchiyamaandOgawa,1970
Injectionof20E(0.1–10mg/kg)inmicereduces
hyperglycaemiaprovokedbyalloxanorglucagon , and
increasesglucoseincorporationintoglycogenand
proteins
Yoshida etal. ,1971
Dietary20E(5mg/kg)for25daysincreasesglycogen
contentinheart , liverandmusclesofrats
Syrov etal. ,1975a;Aizikov etal. ,1978
Antidiabeticagentscontaining20Eorinokosterone  TakahashiandNishimoto,1992
Dietaryadministrationof20E(5mg/kg)orother
ecdysteroidsreducesalloxan-inducedhyperglycaemia
inrats
Syrov etal. ,1997a
20Einoralantidiabetic preparations  Yang etal. ,2001
InjectionsofE(10-50 Pg/kg)reducedenovo
cholesterolbiosynthesisinrats
Lupien etal. ,1969
Dietary20E(0.1mg/kg/day)for30daysprevents(=
hasantiradicalproperties)free-radicallipid
peroxidationofmembranesintissuesfromvitaminD-
deficientrats
Kuzmenko etal. ,1997
20Einvitropreventslipidperoxidationinliposomes
micelles
Osynskaya etal. ,1992;Kuzmenko etal. ,2001
Analgesicscontaining20E  Takemoto etal. ,1988
20EexertsaneuromodulatoryactiononGABA A
receptorofratcorticalneurons
Tsujiyama etal. ,1995;Sasa etal. ,1996;Okada et
al.,1998
Cerebralneuron protectiveeffectsof20E  Aikake etal. ,1996
20Ehasantiepilepticeffectsonrats Hanaya etal. ,1997
20Ehasprotectiveeffectsonamnesiainducedby
diazepamandalcohol
Xu etal. ,1999
Carbohydrate
metabolism
Growth
Cellproliferationand
differentia-tion
Reproduction,
development
Proteinmetabolism
Lipidmetabolism
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established. In fact, through a stimulation of protein synthesis (and/
or a reduction of protein catabolism), ecdysteroids would increase
the lean body mass. In pigs, doses of 0.2-0.4 mg/kg/day resulted in
better nitrogen retention and a body weight increase of 112-116%
relative to controls, while food consumption was lowered by 11-
17% (Kratky et al., 1997). Other experiments used diets
supplemented with ecdysteroid-containing plants (e.g. Rhaponticum
carthamoides) and reported similar growth-promoting effects on
pigs over a 30-day period (Selepcova et al., 1993b). In quails, 20E
in the diet promoted increased growth (115% of controls), but this
was associated with a decreased index of food conversion (Sláma
et al., 1996). From these data, it appears difficult to draw general
conclusions.
Ecdysteroids and physical performance
20E is claimed to have tonic properties (Abubakirov et al.,
1988). Indeed it stimulates muscle growth, provided that protein
supply is adequate. Such anabolic effects result in increased physical
performance without training (Chermnykh et al., 1988). This was
for instance demonstrated using the forced swimming test with rats:
animals given ecdysteroids for one week were able to swim for
significantly longer times (Azizov and Seifulla, 1998). These effects
are similar to those of anabolic steroids. 20E is also able to increase
muscle ATP content in vitamin D-deprived rats (Kholodova et al.,
1997).
Ecdysteroids: effects on cellular proliferation and differentiation
Wound-healing effects of ecdysteroids have been described
(Syrov and Khushbatkova, 1996; Darmograi et al., 1998). 20E
(applied at 0.1% w/w in liposomes) shortens the duration of skin
repair after superficial wounding and 20E (2 x 10–4M) stimulates
keratinocyte differentiation in vitro (Detmar et al., 1994), an effect
measured by the increase of the activity of transglutaminase (an
enzyme involved in protein connection through isopeptidic bond
Phytoecdysteroidshaveantiatherosclerotice ffects Syrov etal. ,1983
20Ecaneliminatearrhythmiainducedbyocclusionof
theleftcoronarydescendingbranchorbyaconitineor
calciumchloride
KurmukovandYermishina,1991
20Ecaneliminatearrhythmiainducedbyaconitine Yang etal. ,1996
20E(0.25-2.5mg/kg)canrestorenormalrheologic
indices(fibrinogenconcentrationandviscosity)of
bloodfromratswitha“highbloodviscosity
syndrome”inducedbycerebralischemia
Plotnikov etal. ,1998
20EcancounteractthedamagesinducedbyTNF D on
humanumbilicalveinendothelialcells
Wu etal. ,1998b
20Ecanbeusedinpreparingmedicinefor
angiocardiopathy
Wu,2001
Dietary20Eimprovesliverregenerationafter
chemicallyinduceddamage
Syrov etal. ,1981b,1992;Badal’yants etal. ,1996
Dietary20Eorcyasterone(5-50mg/kg)stimulatebile
secretioninrats
Syrov etal. ,1986b
Kidney Dietary20E(5mg/kg)restoresnormalglomerular
filtrationrateandsuppressesalbuminuriainrats
treatedwithanephrotoxicmixture
SyrovandKhushbatkova,2001
Dietary20E(10-20mg/kg/day)hasanti-inflammatory
propertiesinmiceandrats
KurmukovandSyrov,1988
Dietary20Eprotectsgastricmucosaagainst
ulcerogenicchemicals
Syrov etal. ,1989
Dietary20Estimulates primaryimmunereaction Kuzmitsky etal. ,1990
20E(1pM–10 PM)andotherecdysteroidsenhance
DNAsynthesisinmitogen-stimulatedlymphocytesin
vitro
Fomovska etal. ,1992
20E(10
–9–10
–5M)inhibitshistaminereleaseby
mastcells
Takei etal. ,1991
Dietary20Epromotesthymusweightincreaseinrats Gizatullina etal. ,1994
20E(7.5.10
–1 3–7.5.10
–8M)activatehuman
lymphocytesinvitro(E-rosetteformation,agar
migrationtest)
Trenin etal. ,1996
Dietary20E(5mg/kg)hasnoeffectonexperimentally
inducedinflammatoryprocesses(pleuresia,arthritis)
inrats
Taniguchi etal. ,1997
20E(1 PM)stimulatesT-cellCD2presentationin
vitro
TreninandVolodin,1999
20Ecanbeused forthetreatmento fherpeszoster VargasGonzalez,1986
Administrationof20Etorabbitsreducesinfectionby
protozoa (Lambliaduodenalis,Flagellates)
Syrov etal. ,1990
20E(200 Pg/ml)possessesantibacterialand
antifungalactivities
Ahmad etal. ,1996
20Eanditsacetateshaveantimicrobialactivities Volodin etal. ,1999
Liverfunctionand
detoxification
mechanisms
Defencesystems
Antibioticactivity
Heartandcirculatory
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formation). Accordingly, ecdysteroids show psoriasis-inhibiting
effects (Inaoka et al. 1997). These results have led to many patents
concerning the use of ecdysteroids in cosmetics (Lin and Lin, 1989;
Meybeck and Bonté, 1990, 1993; Meybeck et al., 1994; Tsuji et
al., 1995a&b; Darmograi et al. 1998; Meybeck 1999a&b). In this
context, the incorporation of 20E or its acyl ester (2,3,22-
tripalmitate) into liposomes has been tested as a slow-release form
(Politova et al., 2001).
20E administered orally to rats (5 mg/kg) accelerates the
healing process after an experimental bone fracture (Syrov et al.,
1986a), and the same molecule (10-100 ng/ml) can stimulate the in
vitro proliferation of rat osteosarcoma UMR106 cells (osteoblasts)
by 41% (Gao and Wang, 2000). Similarly, 20E stimulates
proliferation of human umbilical vein endothelial cells (Lin et al.,
1997; Wu et al., 1998b), and several phytoecdysteroids can stimulate
erythropoiesis in rats (Syrov et al., 1997b).
The effects of ecdysteroids on tumorous cell proliferation
are somewhat conflicting: Lagova and Valueva (1981) reported that
20E (0.1-300 mg/kg, subcutaneous injections for 5 days) was mainly
ineffective on tumour growth in mice, but it stimulated the growth
of mammary gland carcinomas in mice and rats. El-Mofti (1987,
1994) reported that E was able to induce neoplastic lesions in toads
and mice; other authors reported inhibitory effects on tumor cell
proliferation (Hirono et al., 1969; Burdette, 1974; Shibatani et al.,
1996). More recently, Konovalova et al. (2002) showed that injected
20E had a synergistic effect with low doses of an antitumour drug
(cis-platin). Most probably, the results may differ according with
the cell types, the nature and concentration of ecdysteroids used,
and this clearly requires more extensive studies. In addition,
genoprotective effects of ecdysteroids have been reported (Gubskii
et al., 1993; Levitskii et al., 1993a&b, 1996; Chabanny et al., 1994);
ecdysteroids can prevent chromatin damages induced by various
chemicals.
Ecdysteroids and protein synthesis
Stimulatory effects of ecdysone on protein synthesis were
reported as early as 1963 (Burdette and Coda, 1963), and the
discovery of phytoecdysteroids made these molecules available in
large amounts for pharmacological assays. It was rapidly shown
that ecdysteroids were able to stimulate protein synthesis in mouse
liver (Okui et al., 1968; Otaka et al., 1968, 1969a&b). In fact, it
was shown that 20E stimulates the incorporation of [14C]leucine in
a cell-free translation system (rat liver polysomes), i.e. it increases
the efficiency of the translational machinery (Syrov et al., 1978).
Such conclusions have been confirmed and extended to other tissues,
especially heart and muscles (Syrov et al., 1975a; Aizikov et al.,
1978; Khimiko et al., 2000). Recent structure-activity studies (Syrov
et al., 2001) as measured by a stimulation of [14C] aminoacid
incorporation into proteins showed that among the compounds tested
turkesterone was the most active, followed by cyasterone and 20E.
Table 2. Effects of ingested or injected ecdysteroids on growth of various vertebrate species (in red, reference to patents).
Cyas: cyasterone; E: ecdysone; 20E: 20-hydroxyecdysone; PonA: ponasterone A; Turk: turkesterone; VitE: viticosterone E
i.p. : intraperitoneal injection ; i.v.: intraveinous injection.
Species Ecdysteroids Dailydose Modeof
administration
Durationof
treatments(days)
Effects References
Mice 20E,Cyas 0.005-0.1mg peros 90 Increasedprotein
synthesisinliverand
kidney
Hikino etal. ,1969
Mice Turk 5mg/kg i.p. Increasedliverprotein
synthesis invivo and
invitro
Syrov etal. ,1978
Mice(juvenilesand
adults)
20E 0.1,0.5,1
mg
i.p. 30 Increasedgrowthof
juvenilefemalesand
ofadultsofbothsexes
Stopka etal. ,1999
Rats(29-dayold) E,20E,
PonA
2,10,50mg peros 5 Noeffectongrowth
rate
Matsuda etal. ,1970
Increasedmuscleand
liverweight
SyrovandKurmukov,
1975a,b
Noandrogeniceffect Syrov etal. ,1975b
Increasedmuscleand
liverweight
Noandrogeniceffect
Rats(juveniles,adults
andovariecto-mized
juveniles)
20E 5mg/kg i.p. 7 Increasedbodyweight
andgrowthofliver,
kidneys,muscles
Syrov etal. ,1981a
Sheep  E  0.02 Pg/kg  peros,ori.v. 35-150  Increasedgrowthrate
ofbodyandofwool
PurserandBaker,
1994
Pigs 20E 0.2-0.4
mg/kg
peros 30 Increasedgrowthand
highernitrogen
retention
Krátky etal. ,1997
Japanesequails 20E 20,100,500
mg/kgof
food
peros 28 Increasedgrowth Sláma etal. ,1996
SyrovandKurmukov,
1976c
10
7 5mg/kg peros
0.5-10mg/kg i.p. Rats(castrated
juveniles)
VitE,Turk
Rats(juvenilesand
adults)
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Ecdysteroids and glucose metabolism
It was shown early on (Table 3) that 20E given per os to
rats reduces hyperglycaemia induced either by glucagon or by
alloxan treatment (Matsuda et al., 1970; Uchiyama and Ogawa,
1970; Yoshida et al., 1971, Uchiyama and Yoshida, 1974). In fact,
20E stimulates the incorporation of glucose into glycogen and
protein in mouse liver (Yoshida et al., 1971) and more generally it
enhances glucose utilization by tissues (Syrov et al., 1997a). The
mechanism involved seems to be an increase of tissue sensitivity to
insulin (Kosovsky et al., 1989) and preparations containing
phytoecdysteroids have been proposed as oral antidiabetics
(Takahashi and Nishimoto, 1992; Yang et al., 2001). Depending
on the extent of hyperglycaemia, phytoecdysteroid effects may be
more or less pronounced that those of manilil, a widely used
pharmacological molecule (Kutepova et al., 2001).
Ecdysteroids and lipid metabolism
Ecdysteroids display hypocholesterolaemic effects (Lupien
et al., 1969; Mironova et al., 1982; Syrov et al., 1983), through a
reduction of cholesterol biosynthesis and an increase of its
catabolism (Uchiyama and Yoshida, 1974). 20E (5 mg/kg per os)
stimulates the conversion of cholesterol into bile acids in rats (Syrov
et al., 1986b), and such an effect is reminiscent of some oxysterols
(Schroepfer, 2000). In connection with these effects, ecdysteroids
may also have antiatherosclerotic actions (Matsuda et al., 1974;
Syrov et al., 1983). Intraperitoneally injected 20E (0.5 mg/ kg in
rats) also enhances [14C]acetate incorporation into liver triglycerides
and reduces triglyceride lipase activity (Catalán et al., 1985).
Ecdysteroids: a “universal medicine”?
An impressive number of papers dealing with ecdysteroid
effects are available in the literature. They concern almost every
physiological function, and we will give below a brief insight of
the published data. It must  be noted, however, that in many instances
that, in addition to the difficulties caused by language barriers, the
experiments are not always described with all the desirable details.
Ecdysteroids improve nervous function: in early studies,
it was shown that 20E induced glutamic decarboxylase (an enzyme
Table 3.  Effects of ingested or injected ecdysteroids on carbohydrate metabolism (in red, reference to patents).
involved in GABA biosynthesis) in rat brain (Chaudhary et al.,
1969), and that E was able to induce acetylcholinesterase in rat
brain too (Catalán et al., 1984). More recently, ecdysteroids were
shown to represent neuron-protective agents; they reduce glutamate-
induced cell death in cortex neurons of rat foetuses and they are
proposed as a therapy against mental and behavioural disorders
(Aikake et al., 1996). In addition, they may protect against amnesia
induced by diazepam or alcohol (Xu et al., 1999). Similar
neuroprotective effects have been described for progesterone and
oestradiol mixtures in animal models of neurodegeneration (Vongher
and Frye, 1999).
Ecdysteroids stimulate hepatic functions: 20E accelerates
recovery after hepatitis induced by heliotrine treatment (Syrov et
al., 1981b). 20E and other ecdysteroids (turkesterone, cyasterone)
administered (10 mg/kg) to rats with hepatitis induced by
subcutaneous injection of carbon tetrachloride prevent its
hepatotoxic action (Syrov et al., 1992). Moreover, a pretreatment
with 20E (5 mg/kg) for one week will reduce the effects of a
subsequent heliotrine treatment (Badal’yants et al., 1996).
Ecdysteroids improve heart and lung function: 20E has
been recommended for the prevention of myocardial ischaemia,
arrhythmia and is described as enhancing VEGF expression (Wu,
2001). An antiarrhythmic effect of 20E was also reported by
Kurmukov and Yermishina (1991) and Yang et al. (1996), and an
extract of Leuzea carthamoides containing high amounts of 20E
also showed a similar effect (Maimeskulova and Malslov, 2000).
In rabbits experimentally rendered atherosclerotic (by a high
cholesterol diet), 20E (10 mg/kg/day per os) given for 28 days was
able to increase Na+/K+ ATPase in myocardium (Khushbaktova et
al., 1987). Intravenous injection of 20E showed also a therapeutic
effect after lung contusion (Wu et al., 1997, 1998a).
Ecdysteroids improve renal function: when rats are given
a nephrotoxic mixture (uranyl acetate + glycerol), 20E (5 mg/kg)
seems thereafter able to restore a normal glomerular filtration rate
and to suppress albuminuria (Saatov et al., 1999; Syrov and
Khushbaktova, 2001).
Ecdysteroids and the immune system: various
immunomodulatory effects of ecdysteroids have been described.
Single intraperitoneal injections of various ecdysteroids (20E, 2dE,
Cyas: cyasterone; E: ecdysone; 20E: 20-hydroxyecdysone; Ino : inokosterone A; Turk: turkesterone.
Species Ecdysteroids Dose Modeof
administration
Durationof
treatments
(days)
Effects References
RatsorMice 20E 0.5mg/kg i.p. Hypoglycaemic Yoshida etal. ,1971;
Uchiyamaand
Yoshida,1974
Rats 20E 5mg/kg peros 15 Recoveryofliver
mito-chondrial
functionafteralloxan
treatment
Tashmukhamedova
etal. ,1985Syrov et
al.,1992
Rats 20E Increasesensitivityto
insulintreatmentin
experimentaldiabetes
Kosovsky etal. ,1989
Humans  20E,Ino peros  Antidiabeticeffects  Takahashiand
Nishimoto,1992
Rats 20E,Cyas,Turk peros Decreaseof
glycaemiaindiabetic
animals
Syrov etal. ,1997a
Humans  20E+20E2Ac  – peros  – Antidiabeticeffects  Yang etal. ,200115 Lafont R., Dinan L. 2003.  Practical uses for ecdysteroids in mammals including humans: an update.  30pp.  Journal of Insect Science, 3:7, Available online:
insectscience.org/3.7
2d20E, polB, turkesterone, 1-5 mg/kg) increase the concentration
of antibody-forming cells in the spleen of mice immunised with
sheep red blood cells (Sakhibov et al., 1989). Low (7.5x10-12-7.5x10-
8 M) concentrations of 20E induce the activation (E-rosette formation
test) of human lymphocytes  (Trenin et al., 1996; Trenin and
Volodin, 1999). Low to moderate (10-12-10-5 M) concentrations of
20E or other ecdysteroids stimulate, whereas higher (10-4M)
concentrations eventually inhibit, DNA synthesis in concanavalin
A – activated lymphocytes (Kuzmitsky et al., 1990; Fomovska et
al., 1992; Chiang et al., 1992).
20E (10-20 mg/kg/day per os) has antiinflammatory
properties similar to cortisone acetate in rats and mice (Kurmukov
and Syrov, 1988; Fomovska et al., 1992) and turkesterone improves
lung defence mechanisms in diabetic rats (Najmutdinova and Saatov,
1999). 20E was shown to inhibit in a dose-dependent fashion (10-9-
10-4 M) histamine release from rat peritoneal mast cells induced by
anti-IgE or concanavailin A (Takei et al., 1991). Taniguchi et al.
(1997), however, could not observe any antiinflammatory effect of
20E given orally to rats (5 mg/kg/day for 7 days).
Ecdysteroids have antioxidant properties: 20E has
antioxidative and anti-free radical properties (Osynska et al., 1992)
and it can thus reduce lipid peroxidation (Kuzmenko et al., 1997,
2001). Several models were used in these studies, as the
chemiluminescence of blood serum induced by H2O2 using rats
receiving a vitamin D-deficient diet eventually supplemented with
0.1 mg 20E/kg per day, or the uptake of oxygen by methyl linoleate
micelles in the presence or absence of 20E.
Are ecdysteroids toxic to microorganisms?: there are a few
reports about antimicrobial activity of ecdysteroids. However,
Ahmad et al. (1996) reported antifungal and antibacterial activity
of 20E at rather high concentrations (between 100 and 400 µg/ml,
i.e. 2-8 x 10-4 M). An antimicrobial activity of 20E and its acetates
was also observed by Volodin et al. (1999). Toxic effects on protozoa
have also been reported; rabbits receiving 20E per os (5 mg/g/day
for 3 months) showed a reduced infection with Lamblia duodenalis
(Syrov et al., 1990), and the improvement of ruminant productivity
by ecdysone was also interpreted by its toxicity towards rumen
protozoa (Purser and Baker, 1994).
Ecdysteroids are not toxic to vertebrates: ecdysteroids have
a very low toxicity (LD50 > 6g/kg), they are not hypertensive and,
in spite of their anabolic action, they would have neither androgenic
nor oestrogenic (or antioestrogenic) effects; they induce no
virilisation and they do not induce significant changes in castrated
animals (e.g. Prabhu and Nayar, 1974). All together this suggests
that ecdysteroids are attractive compounds for a wide array of uses,
which have been proposed, and of course it would be of particular
interest to understand more precisely their mode(s) of action in
mammals.
Genomic and/or non-genomic effects of ecdysteroids?
Do ecdysteroids have genomic effects on vertebrates?
In insects, ecdysteroids have well-known genomic effects
which involve nuclear receptors (see Section 2). When considering
the molecules in 3-dimensions, it is clear that they show striking
differences to vertebrate sex or adrenal steroids, and their full
cholesterol side-chain most probably prevents any binding to the
receptors of these vertebrate hormones. Recently, however, it has
been found that some previously “orphan” nuclear receptors (e.g.
LXR, PXR) bind endogenously produced oxysterols (Janowski et
al., 1999 ; Schroepffer, 2000) or have a broad specificity and may
bind a wide array of xenobiotics including several steroids (Jones
et al., 2000). Given this broad ligand specificity, these proteins might
rather function as “endocrine sensors” rather than “true receptors”
(Evans, 2002). So, until ecdysteroids are directly tested for binding
to such receptors, it remains conceivable that they may have
transcriptional effects through binding to some nuclear receptor(s);
indeed early studies showed a rapid in vivo stimulation by 20E of
the incorporation of [14C]orotic acid into RNA in mouse liver
(Uchiyama and Otaka, 1974).
Ecdysteroids: membrane effects?
Membrane effects of steroids are nowadays well
documented and they may proceed through three different pathways
(Figure 7). According to Brann et al. (1995), these effects may either
involve: (1) the dissolution of ecdysteroids in the membrane bilayer
and a change in the environment of some membrane proteins (and
hence of their activity), (2) their interaction with a specific membrane
receptor, which will activate some transduction mechanism, or (3)
their binding to a modulatory site of the receptor for another
molecule. These different effects are not mutually exclusive. Very
recently, a membrane progestin receptor involved in fish oocyte
meiotic reinitiation was cloned and its physiological relevance was
fully established (Zhu et al., 2003).
Dissolution of edysteroids in the membrane lipid bilayer
In order to test for the first hypothesis, Tuganova
and Kotsyuruba (1996) developed experiments designed
to analyse the dissolution of ecdysteroids in human
erythrocyte membranes. They did not perform direct
experiments, i.e. by measuring the incorporation of
radiolabelled ecdysteroids. In a first set of experiments,
erythrocytes were first incubated with various steroids (10-
6 M) and then with [3H]cholesterol; both 2d20E and 20E
pretreatments reduced the radioactivity associated with
membrane fractions. In a second set of experiments, the
authors first incubated erythrocytes with various
concentrations of 20E (10-14 to 10-10 M) then with either
radiolabelled cholesterol, cholecalciferol or calcitriol; 20E
reduced mainly calcitriol incorporation. Such experiments
support the idea that ecdysteroids can be incorporated into
membrane bilayers, although they do not constitute an
absolute proof. It is tempting to make a relation between
Figure 7. Three possible ways for a membrane effect of ecdysteroids (adapted
from Brann et al., 1995).16 Lafont R., Dinan L. 2003.  Practical uses for ecdysteroids in mammals including humans: an update.  30pp.  Journal of Insect Science, 3:7, Available online:
insectscience.org/3.7
these results and the rapid effect of 20E on Na+/K+ ATPase
activity in D. melanogaster salivary gland cells (Schneider
et al., 1996).
Rapid membrane effects
A rapid increase of cGMP and a decrease of cAMP
levels in mouse plasma, together with a decrease of PKA
activity in liver were described 40 min after an
intraperitoneal injection of 10 µg 20E (Catalán et al.,
1979a&b, 1982). More recently, it was shown that 20E
evokes rapid (1-2 min) and transitory effects on membranes
(Kotsyuruba et al., 1995a-c, 1998a&b, 1999); 20E increases
the pool of free arachidonic acid and the synthesis of
leukotrienes and prostaglandins. Such responses were
observed with different cell types (hepatocytes, erythocytes,
lymphocytes, macrophages etc.). In many instances the
effects of 20E resemble those evoked by calcitriol (1,25OH-
D3), a molecule often used for comparison by those working
on ecdysteroid pharmacology (Barsony and Marx, 1988).
The same effects were also produced by 20E bound to
magnetite nanoparticles (Mykhaylyk et al., 1999; 2001), a
formulation which should prevent 20E diffusion into target
cells, and thus restricting its possible action(s) to the plasma
membrane level.
We should emphasise here that ecdysteroids can
be recognised by membrane receptors in arthropods:
ecdysteroids can be detected by taste cell receptors both in
Crustacea (Tomaschko, 1999) and insects (Tanaka et al.,
1994; Descoins and Marion-Poll, 1999), and in vertebrates
too steroids can work as pheromones (see e.g. Sorensen et
al., 1990). Thus, such a mode of action is conceivable.
Neuromodulatory actions
Such effects are well documented for vertebrate
neurosteroids, which may modulate the response of
Figure 8. A working hypothesis for ecdysteroid action on mammalian cells: a
stimulation of the Akt/PKB pathway would explain a large set of the described
effects of 20E on mammals (see text for details).
Bad: a proapoptotic factor, which is inhibited upon phosphorylation by Akt;
Glut4: glucose transporter type 4; GSK3: glycogen synthase kinase-3; IL3:
interleukin-3; INS: insulin; S6K: ribosomal protein S6-kinase.
neurotransmitter receptors to their cognate ligands. The
binding of the steroid alone has no apparent effect. Thus,
the GABAA receptor possesses (in a domain separate for
the neurotransmitter binding site) a binding site for steroids,
which may therefore modify the response to GABA. In a
similar way, 20-hydroxyecdysone showed a
neuromodulatory effect on GABAA receptor of rat cortical
neurons (Tsujiyama et al., 1995; Sasa et al., 1996), although
this was observed for rather high concentrations (10-100
µM). In connection with this effect, 20E showed an
antiepileptic activity in rats (Hanaya et al., 1997); when
20E was given orally (100-200 mg/kg) to spontaneous
epileptic rats, it was able to reduce tonic convulsions.
Some recent data
Recently, Constantino et al. (2001) fortuitously made a
crucial observation. Using  the Invitrogen® ecdysteroid-inducible
expression system to analyse the transduction mechanisms of
interleukin-3 (IL-3) in a pro-B lymphocyte cell line, they found in
control experiments that murA and ponA were able to potentiate
the IL-3-dependent activation of PI 3-kinase/Akt pathway in non-
transformed cells.
Given the central role of the Akt/PKB pathway in
mammalian cell metabolism (e.g. Brazil and Hemmings, 2001;
Whiteman et al., 2002), such results provide an interesting basis
for explaining in a single way many effects of ecdysteroids on
mammals, as concerns their hypoglycaemic, antiapoptotic and
anabolic actions (Figure 8). The available data do not allow to decide
whether edysteroids act on the IL-3 receptor itself or on a
downstream step.
Where is 20-hydroxyecdysone found?
Phytoecdysteroids are found in many plant species, where
they can reach concentrations above 1-2% of the plant dry weight
(e.g. Lafont, 1998, Dinan, 2001). Ecdysteroid-rich species are found
among ferns and angiosperms and some of these species are either
very common (e.g. the fern Polypodium vulgare) or they are
cultivated on a large scale for their pharmacological properties (e.g.
Leuzea, Pfaffia, Cyanotis). Given the still limited market at the
moment, a few plant species only (Table 4) are currently used as a
source of phytoecdysteroids: (1) Leuzea (= Rhaponticum)
carthamoides (Asteraceae) from Eastern Europe countries, where
it is cultivated as a remedy in traditional medicine, (2) Pfaffia (in
fact a group of related species) = Brazilian ginseng (= Suma), again
a plant used in traditional medicine and (3) Cyanotis vaga or C.
arachnoides, a monocotyledonous plant, extracts of which are used
on a large scale also for the synchronization of spinning in silkworm
larvae (Guo, 1989; Chandrakala et al., 1998).
Over 140 different preparations containing ecdysteroids for
oral use can be found on the market (Table 5). We may distinguish
several categories among them: (1) those containing crude or semi-
purified plant extracts (plant powders, or alcoholic extracts - elixirs)
and (2) those containing “pure” 20E or a defined ecdysteroid
mixture. Most of them are proposed for use by bodybuilders, but
some have been designed for more specific users (e.g. golfers), or
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in at least two cosmetic preparations (Hydrastar and Phenomen A
from Christian Dior).
The impressive development of preparations containing
ecdysteroids suggests that this class of molecule has indeed at least
some of the claimed effects. The scientific justification for such
commercial developments relies, however, on just a few references
(ca. 10), often with the same ones being cited to support quite
different effects.
Species Family Localname Partoftheplantused
Ajugaturkestanica Labiatae Wholeplants?
Cyanotisvaga Commelinaceae Whole plantsand/orroots
Cyathulacapitata Amaranthaceae ChuanNiuHsi Roots
Leuzea(=Rhaponticum)carthamoides Asteraceae Maral Roots,seeds
Pfaffiairesinoides Amaranthaceae Suma,ParaToda Roots
Pfaffiapaniculata Amaranthaceae Suma Roots
Pfaffiastenophylla Amaranthaceae Suma Roots
Polypodiumaureum Ferns Calaguala Rhizomes
Polypodiumlepidopteris Ferns Samambaia Rhizomes,leaves
Polypodiumvulgare Ferns commonpolypody Rhizomes?
Table 4. Plants currently used to obtain the ecdysteroids used for various preparations
Table 5. Preparations based on purified ecdysteroids or on ecdysteroid-containing plant powders/extracts.
Table 5.  Continued on next page
Conclusion
Ecdysteroids are probably the most abundant steroids in
nature because they are produced not only by arthropods, but also
by many plant species. They seem to display a wide array of
pharmacological effects on vertebrates, many of which are
beneficial. However, these claims require more thorough validation
and clinical testing. Ecdysteroids are used by an increasing number
Nr Product Supplier Web address Plantsource(s)
Leuzea
+Cyanotis
2 ACT-SUM™ 7thMillenium
Nutrition
http://www.diabetestea.com/actsum.html Pfaffia
3 AdaptogenN MuscleAndSport
Science(MASS)
http://www.musclemass.com/prohormone.html Pfaffia
4 Adrena+ Greens+™ http://www.greenspluscanada.com/fr/infonp.htm Pfaffia
5 Advanced Compound2 AdvancedLabs http://www.reach4life.com/details.asp?ProdID=4534 Pfaffia
Leuzea
+Cyanotis
7 AmazoniaImmuno
Forte
Nutrisana http://www.nutrisana.com/html/amazonia_fr.htm Pfaffia
8 AnimalMethoxyStak UniversalNutrition http://www.fitnessfirstusa.com/details.asp?item=7781 ?
9 AtomicMuscle MaximusNutrition http://www.maximusnutrition.com/products/MN012.html ?
10 Beta-Builder UltimateNutrition http://www.onlineprotocols.com/product/beta_product.htm ?
11 ß-Ecdysone NuTrex Nutrition http://www.fitnessone.com/load_frames.html?anabolic-products/b-ecdysone ?
12 Beta-Ecdysterone Gennapharm http://www.gennapharm.com/BetaEcdysteroneFrame.asp ?
13 Beta-EcdysteroneStack PEAKNutrition http://peaknutrition.com/betstac90tab.html Pfaffia
14 Beta-Mass 7thMillenium
Nutrition
http://www.diabetestea.com/beta1.html Pfaffia
15 Betaoxytol BSN http://www.bodybuilding.com/store/bsn/beta.html Leuzea
16 Beta-Xcapsules/liquid FlexstarSports
Nutrition
http://primenutrition.com/betbet180cap.html Cyanotis
17 Bicreatol BSN http://www.vigorousliving.net/bsnbic12.html ?
18 Bio-ProPlus BodyAmmo http://www.nutritionblvd.com/284132.html Pfaffia
19 BPS Syntrax http://store.yahoo.com/xsportsnutrition/syntraxbps.html Leuzea
20 BrazilianGinseng ParadiseHerbs http://www.iherb.com/braziliangin.html Pfaffia
21 BugJuice ? http://www.supervita.com/top12/bugjuice.htm ?
22 ChangingTimes™ Nature’sPlus http://www.naturesplus.com/products/ Pfaffia
23 ClearEnergy GardenofLife http://www.iherb.com/clearenergy.html Leuzea
24 Creabolicfizz MaximumHuman
Performance
http://www.fitnessfirstusa.com/details.asp?item=7138 Pfaffia
25 Cyclone Maximuscle http://gymratz.co.uk/bodybuilding-supplements/item44.htm ?
26 Desire-X MasoNnatural http://www.vitaminsalon.com/sexenhancers/hornygoatweed/goatweed.htm Polypodium
6 ALL-iN1 SportsNutritionNet http://www.sports-supplements.co.uk/reviews/sportsnutrition/allin1.shtml
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27 EcdyMaxHP EAS http://www.bodybuilding.com/store/eas/ecdymax.html ?
28 Ecdy-20 MRM http://www.metabolicresponse.com/detail.asp?id=86 Leuzea
29 EcDyBol BodyonicsPinnacle http://www.pinnaclebody.com/ecdybol.htm Leuzea
30 Ecdy-Bolin ? http://www.trulyhuge.com/ecdy-bolin.htm Leuzea
31 Ecdy-Force PEAKNutrition http://www.peaknutrition.com/ec180tab.html Pfaffia
32 Ecdylean NuTrexNutrition http://www.fitnessone.com/anabolic-products/ecdylean.html Leuzea?
33 Ecdy-Mass™ GaspariNutrition http://www.richgaspari.com/products/ecdymass.htm Leuzea
34 Ecdymax™ ARNutrition http://www.bodybuilding.com/store/ar/ecdymax.html Leuzea
35 Ecdysone ReflexNutrition http://www.creatinestore.co.uk/productsinfo/Ecdysone_x_90_Capsules.asp Cyanotis
36 Ecdysten ThermoLife
International
http://www.thermolife.com/Products-Ecdysten.html Leuzea
37 Ecdysterone ZOELabs http://www.tigerfitness.com/Ecdysterone.htm ?
Leuzea
+Cyanotis
39 EcdyVonePlasma Prolab htmhttp://www.bodyworks-nutrition.com/ecdyvone-plasma.html Cyanotis
40 Ekdisten BodybuildinG
Estonia
http://www.bodybuilding.ee/est/texts/toit/ekdisten.htm Leuzea
41 EliteAthlete™ MDHealthline http://mdhealthline.com/cgi/sgx/store/web_store.cgi?cart_id=134.157.
163.233&page=elite.html&afnum=1897
Cyanotis
42 Enact+ Greens+™ http://www.masantesexuelle.com/nouvelle6.htm Pfaffia
43 EquineGold EquineGold? http://natural-s tress-management.com/equine_gold.htm Leuzea
44 Eroto2Caps™ 7thMillenium
Nutrition
http://www.diabetestea.com/erotojoy.html Pfaffia
45 EspeciallyYours Nature’sPlus http://www.naturesplus.com/products/ Pfaffia
46 Excite Dynamitize
Nutrition
http://www.affordablesupplements.com/excite.asp Polypodium
47 FemActin HerbalActives http://www.healthclub.ru/natures/femactin.php Pfaffia
Leuzea+
Pfaffia
49 Fitnesky Slovakofarma/Interc
aps
http://www.ishop.purus.cz/start.php?menu=E%7CX9&soubor=podkat.php Leuzea
Leuzea
+Cyanotis
51 HornyGoatWeed BodyonicsPinnacle http://www.marigarden.com/hgw/index.html Polypodium
52 HornyGoatWeed Nature’sA........... http://www.horny-goat-weed-maca-pure.com/ingredients.htm Polypodium
53 HornyGoatWeed HerbalRemedies
USA™
http://www.herbalremedies.com/horgoatweed6.html Polypodium
50 20-H TKE(TheKutting
Edge)
http://www.tkefitness.com/20h.asp
48 FirmEase GeroVita
International
http://www.gvistore.com/gbd/fxa.html
38 EcdyVone Prolab http://www.fitnessfirstusa.com/details.asp?item=7701
54 HornyGoatWeedPlus NaturalMen’s
Health?
http://www.onlynaturalinc.com/store/hornygoat.html Polypodium
55 HumanoPro GEN
®Human
Performance
Nutrition
http://www.pacific-nutrition.com/whey-humanopro.htm Leuzea
56 Hydra-Star ChristianDior http://www.auravita.com/factfile.asp?pCode=PACH11050&pType=5 Cyanotis
57 IMH-Ecdysterone Supplements
Research&
Advancements
(SRA)
http://www.healthnutwarehouse.com/imhec90cap.html ?
58 Immunectar® Nature’sPlus http://www.naturesplus.com/products/ Pfaffia
59 IsoStakAFC UniversalNutrition http://www.sportvoeding.nl/isostak.html ?
61 Lean65MRP Iron-Tek http://www.fitnessone.com/load_frames.html?mrp-products/lean_65_mrp Cyanotis
62 Leuzeadrops Slovakofarma http://www.aha.ru/~slovakof/products/leuzea.html Leuzea
63 LiquidDynamite BeastSports http://www.buyjustnatural.com/liquiddynamite.html ?
64 Maralan FirmaKr˘en http://http://www.kren.cz/maralan.htm Leuzea
65 MaralanSuper FirmaKr˘en http://http://www.kren.cz/maralan.htm Leuzea
66 MaxabolII Maxam
Nutraceutics
http://ssl.ipns.com/maxamssl/MAXAM_ASP_ViewProduct_LongDescription.asp?ProductIND
X=35
Pfaffia?
67 MedicinalCyathula
Root
Sinoking http://sinoherbking.com/sk3/41052.html Cyathula
Pfaffia
+Cyanotis
69 MethoxyECD™
Xtreme
EAS? http://www.usadiamondnutrition.com/MethoxyECDxtreme.html ?
70 MethoxyFactorHP EAS http://www.musclesurf.com/metfachp50so.html ?
71 MethoxyGro™ Myvitanet
NutritionalProducts
http://myvitanet.com/vitanet/5met100mg60c.html Cyanotis
72 MethoxyPure SportsScience
Research
http://www.sportsscienceresearch.com/pages/mythoxy_pure.asp ?
Methoxy+Ecdysterone
SubligualStack
74 Methoxybol-7 ScientificAdvanced
Nutrition(SAN)
http://store.yahoo.com/ampharma/metbysan.html ?
73 Supplements
Research&
http://www.gotsupplements.com/methoxy-ecdysterone-sublingual-stack. htm#69 Cyanotis
Cyanotis
68 MethoxeronePlus MaxMuscle http://www.maxmuscle.com/PressRelease/methoxerone/methoxerone.htm
60 IT-IdealTransformation
Formula
MiadaSports
Nutrition(NZ)
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75 MethoxybolicX TotalNutritional
Technologies(TNT)
http://www11.netrition.com/tnt_methoxybolic_x_page.html Cyanotis
76 Methoxy-sterone MuscleScience http://www.jkdu.co.za/JKDU_new/jkd_supp/methoxy.htm ?
77 Methoxy-Tek™ Iron-Tek http://www.advantagesupplements.com/birmet60cap.html Cyanotis
78 MethoxyWhey UltimateNutrition http://www.fitnessfirstusa.com/details.asp?item=7709 Cyanotis
79 MSB Syntrax http://www.totalhealthsource.com/SY013.asp ?
80 MuscleDriveHP EAS http://www.sportsupplementsource.com/sportsource/easmusdrivhp.html Cyanotis
81 MuscleDriveHPBars EAS h ttp://www10.netrition.com/eas_muscle_drive_bars_page.html Cyanotis
82 MX-7Extreme GEN®Human
Performance
Nutrition
http://www11.netrition.com/gen_mx7_extreme_page.html Leuzea
83 MyoblastII BodyLifeScience http://www.pinsonsfitness.com/body_life_sciences.html Pfaffia
84 Myo-Blast™ ? http://www.muskelpiraten.com/mpshop/shop.asp?action=visaen&art=CD200 Leuzea
85 MyoMeth ScitechNutrition http://www.healthcenterplus.net/Myometh.htm Leuzea?
86 NaturalSterolExtreme UniversalNu trition http://www.b-fit.com/natsterex90.html ?
87 NewPower Anew? http://www.anew.com.br/02_new_power.asp Pfaffia
88 NorateenII LA™Muscle http://www.norateen.com/docs/norateen2.php3 ?
89 Nu-Nitro-8™ Nutec http://www.nutecperformance.com/productinfo.asp ?
90 Nutrejuva Microlight http://www.microlight.net/nutrejuva2.htm Pfaffia
91 NutriZAC Nature’sPlus http://www.naturesplus.com/products/ Pfaffia
92 Nutrizen Nature’sPlus http://www.natural-distribution.com/produits/natureplus/nutrizen.htm Pfaffia
93 OrganicGermanium NatureMost http://www.totaldiscountvitamins.com/Merchant/germaniumframe.htm Pfaffia
94 PeakPerformance-2 K-9PowerProducts
LLC
http://www.dogzone.com/aprl/ingredie.htm ; http://k9power.com/peak.htm ??
95 Pfaffiapaniculata ? http://www.derivatamedicus.se/produktinfo.asp?artikelnr=1 Pfaffia
96 Pfaffiapaniculata NewDeal http://www.newdeal.ch/pfaffia/ Pfaffia
97 Pfaffiânico PA http://www.anew.com.br/02_pfaffianico.asp Pfaffia
98 Phenomen-A ChristianDior http://www.hyperbelle.com/Tests/phenomenA.html Cyanotis
99 Phytobol ASN http://www.musclesurf.com/phytobol.html Pfaffia
100 PowerMeal Advanced
Pharmaceutical
Research
http://shop.store.yahoo.com/sports-nutrition/powermeal35cho1.html ?
101 PrimavarXtreme AmericanResearch
Labs
http://www.pinsonsfitness.com/primavar_xtreme.html ?
102 PrimeOne PrimeQuest™
International
http://www.whatskillingyou.com/ingredients.html Leuzea
103 PrimePlus PrimeQuest™
International
http://www.primequest.co.za/primeplus.htm Leuzea
104 ProComplexPM OptimumNutrition http://shop.store.yahoo.com/sports-nutrition/procompmchoc.html Cyanotis
105 Pro-Eroto™ 7thMillenium
Nutrition
http://www.diabetestea.com/erotojoy.html Pfaffia
106 PromaxExtreme Maximuscle http://affordablesupplements.co.uk/ProductDetail.asp?ProductID=443 ?
107 ProteinPM™ InteractiveNutrition http://www.interactivenutrition.com/products/proteinpm.php ?
Leuzea
+Ajuga
109 Retibol® EiseltResearch http://www.eiselt.se/produkter/Retibol.htm Leuzea
110 Robofittinktura BioSysteamBT http ://www.vardanet.hu/biosysteam/r.html Leuzea
111 Rus-Olympic Nutri-Tech
InternationalAS
http://www.adaptogeno.com/rus_olympic.htm Leuzea
112 RussianSecret PowerHealth,Inc. http://powerhealth.com/detail.cfm?id=365 Leuzea?
113 SMP Syntrax http://www.bodybuilding.com/store/syn/smp.html ?
114 Stenandiol GermanAmerican
Technologies
http://www.pinsonsfitness.com/stenandiol.html ?
115 Stimaral™ Virobky? http://www.energy.sk/sk/vyrobky/stimaral.htm Leuzea
116 Suma Nature’sWay http://www.n101.com/Static/Products/suma_root_1740051275.html;
http://www.iherb.com/sumbrazginna.html
Pfaffia
117 SumaRoot Frontier http://www.taoherbfarm.com/herbs/herbs/tonic.htm Pfaffia
118 SuMaca™Plus NativeEssence
HerbCompany
http://www.norx.com/smxc.html Pfaffia
119 Sumacazon™ RainforestBio-
Energetics
http://www.pipeline.com/~dan_glick/Rainforest/maca.html Pfaffia
120 SumaCeps™Plus NativeEssence
HerbCompany
http://www.norx.com/smxc.html Pfaffia
121 SumaFlex™Plus NativeEssence
HerbCompany
http://www.norx.com/smxc.html Pfaffia
122 Sumaforme Laboratoire
Holonorm
http://www.clherbs.com/SUMAFORM.htm Pfaffia
123 Sumah-5 TheMillenium
Nutrition
http://www.diabetestea.com/sumah.html Pfaffia
124 Sumax UltimateNutrition http://www.bodybuilding.com/store/un/sumax.html Pfaffia
125 Syn-R-Gy Amerinden http://www.netriceuticals.com/listing.asp?id=70 Leuzea
126 Syntrabol Syntrax http://www.pacific-nutrition.com/ecdy-syntrabol.htm ?
127 TenLives HigherIdeals http:// www.touchalife.com/tenlives.htm Pfaffia
128 TestoIntelligenceStack Ripfast http://www.ripfast.co.uk/ENGLISH/PAGES/TESTO.HTM ?
108 REAP Phyto-longevity,
Inc.
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of humans as anabolic compounds, and it may well be that in the
near future they will also be used on domesticated animals. This is
the reason why new methods of detection and quantification have
been recently proposed (Tsitsimpikou, 2001; Le Bizec, 2002) and
further developments in this area are required. Whether ecdysteroid
use will become controlled (e.g. for high-performance sportsmen
or domestic animals [e.g. race horses]) is still open.
Ecdysteroids have also been successfully developed as
effective inducers for gene switch control systems, several of which
are presently in use. Ecdysteroids and/or bisacylhydrazines fulfil
many of the required criteria, but not all. There are still problems
which need to be overcome (e.g. the need for highly potent ligands
for modified ecdysteroid receptors in transformed mammalian or
plant cells). However, there is clearly great potential in this area.
The future of ecdysteroid-regulated gene switches as an experimental
tool is assured, but the prospects as in vivo systems is more debatable;
the numerous pharmacological effects of ecdysteroids may preclude
the development of their use in humans for gene therapy systems.
This can only be resolved if more effort is invested into examining
the biochemical fate and pharmacological consequences of
ecdysteroids in mammals, especially humans.
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